LIFECORE BIOMEDICAL, INC. Operating Lease Cost
LIFECORE BIOMEDICAL, INC. (LFCR) reported Operating Lease Cost of $148.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. operating lease, cost for the quarter ending 2026-06-30 was $74.00K.
- LIFECORE BIOMEDICAL, INC. operating lease, cost for the quarter ending 2026-03-31 was $74.00K.
- LIFECORE BIOMEDICAL, INC. operating lease, cost for the quarter ending 2025-09-30 was $74.00K.
- LIFECORE BIOMEDICAL, INC. operating lease, cost for the quarter ending 2025-05-25 was $74.00K, a 11.90% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. operating lease, cost for fiscal 2025 was $336.00K, a 2.33% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. operating lease, cost for fiscal 2024 was $344.00K, a 73.25% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. operating lease, cost for fiscal 2023 was $1.29M, a 22.94% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. operating lease, cost for fiscal 2022 was $1.05M, a 54.34% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 7 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $148.00K 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | $74.00K 10-Q · filed 2026-05-06 | |||||
| 2025-12-31 | $172.00K 10-KT · filed 2026-03-16 | |||||
| 2025-09-30 | $74.00K 10-Q · filed 2025-11-06 | |||||
| 2025-05-25 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $148.00K 10-Q · filed 2026-08-05 | $336.00K 10-KT · filed 2026-03-16 | |||
| 2025-02-23 | $74.00K 10-Q · filed 2026-05-06 | $253.00K 10-Q · filed 2025-04-03 | ||||
| 2024-08-25 | $74.00K 10-Q · filed 2025-11-06 | $158.00K derived: sum of 2 quarters · filed 2026-03-16 | ||||
| 2024-05-26 | $84.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $344.00K 10-KT · filed 2026-03-16 | ||||
| 2024-02-25 | $260.00K 10-Q · filed 2025-04-03 | |||||
| 2023-05-28 | $1.29M 10-K · filed 2024-08-26 | |||||
| 2022-05-29 | $1.05M 10-K · filed 2024-03-20 | $2.21M 10-K · filed 2022-09-14 | ||||
| 2021-05-30 | $2.29M 10-K/A · filed 2023-03-16 | $5.79M 10-K · filed 2021-07-29 | ||||
| 2020-05-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-29 | $3.18M derived: sum of 2 quarters · filed 2021-07-29 | $4.75M derived: sum of 3 quarters · filed 2021-07-29 | $6.34M 10-K · filed 2021-07-29 | ||
| 2020-02-23 | $1.63M 10-Q · filed 2020-04-03 | $3.19M derived: sum of 2 quarters · filed 2020-04-03 | $4.79M 10-Q · filed 2020-04-03 | |||
| 2019-11-24 | $1.57M 10-Q · filed 2020-01-02 | $3.16M 10-Q · filed 2020-01-02 | ||||
| 2019-08-25 | $1.59M 10-Q · filed 2019-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |